Human West Nile IgM Capture ELISA Kit (DEIA1982M)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

Size
96T
Sample
serum
Species Reactivity
Human
Intended Use
The West Nile IgM Capture ELISA Kit is designed for the qualitative detection of IgM antibodies to West Nile recombinant antigens (WNRA) in human serum. This test is intended for use for the presumptive clinical laboratory diagnosis of West Nile virus infection in patients with clinical symptoms consistent with meningoencephalitis.
Contents of Kit
1. Coated Microtiter Strips for Human IgM: 1 x 96 wells
2. Sample Dilution Buffer for WN IgM: 1 x 25 mL
3. WN Human IgM Positive Control: 1 x 50 μL
4. WN Human IgM Negative Control: 1 x 50 μL
5. West Nile Antigen (WNRA) for IgM: 1 x 3 mL
6. Normal Cell Antigen (NCA) for WN IgM: 1 x 3 mL
7. Enzyme Conjugate-HRP: 1 x 6 mL
8. Wash Buffer(10x): 1 x 120 mL
9. Wash Solution: 1 x 20 mL
10. Liquid TMB Substrate: 1 x 9 mL
11. Stop Solution: 1 x 6 mL
Storage
Store the kit at 2-8°C. Keep microwells sealed in a dry bag with desiccants. For more detailed information, please download the following document on our website.
Sensitivity
0.962

Citations


Have you cited DEIA1982M in a publication? Let us know and earn a reward for your research.

Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


Twenty Years of Progress Toward West Nile Virus Vaccine Development

VIRUSES-BASEL

Authors: Kaiser, Jaclyn A.; Barrett, Alan D. T.

Although West Nile virus (WNV) has been a prominent mosquito-transmitted infection in North America for twenty years, no human vaccine has been licensed. With a cumulative number of 24,714 neurological disease cases and 2314 deaths in the U.S. since 1999, plus a large outbreak in Europe in 2018 involving over 2000 human cases in 15 countries, a vaccine is essential to prevent continued morbidity, mortality, and economic burden. Currently, four veterinary vaccines are licensed, and six vaccines have progressed into clinical trials in humans. All four veterinary vaccines require multiple primary doses and annual boosters, but for a human vaccine to be protective and cost effective in the most vulnerable older age population, it is ideal that the vaccine be strongly immunogenic with only a single dose and without subsequent annual boosters. Of six human vaccine candidates, the two live, attenuated vaccines were the only ones that elicited strong immunity after a single dose. As none of these candidates have yet progressed beyond phase II clinical trials, development of new candidate vaccines and improvement of vaccination strategies remains an important area of research.

Neuroinvasive Seronegative West Nile Virus in the Setting of R-CHOP Chemotherapy for Diffuse Large B-Cell Lymphoma

INFECTIOUS DISEASES IN CLINICAL PRACTICE

Authors: Yuen, Alexander D.; Liu, Jason Y.; Betancourt, Jaime

West Nile virus (WNV) is a mosquito-borne infectious disease that can produce potentially life-threatening meningoencephalitis in immunocompromised individuals. In 2017, there were 536 human cases of WNV in California, with 43 fatalities reported to the California Department of Public Health. Peak mosquito transmission periods are in the late summer and early fall when mosquitoes are maximally viremic. In addition to risk factors such as advanced age, malignancy, or prior organ transplantation, the probability of progression to severe, neuroinvasive disease has been reported to be significantly higher in individuals suffering from lymphoma receiving rituximab in addition to other oncologic treatments. Here, we describe the case of a patient who recently received chemotherapy with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone for diffuse large B-cell lymphoma, complicated by meningoencephalitis due to seronegative neuroinvasive WNV infection, ultimately resulting in death.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:
Verification code
Click image to refresh the verification code.

Online Inquiry

  Interested in larger quantities ? request a quote!
  Protocol may be improved. Please feel free to contact us to obtain the latest version.!

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

OUR PROMISE TO YOU Guaranteed product quality expert customer support

Inquiry Basket